CSIMarket
 
Edgewise Therapeutics inc   (EWTX)
Other Ticker:  
 
 
Price: $16.3700 $-0.12 -0.728%
Day's High: $16.48 Week Perf: -3.02 %
Day's Low: $ 15.79 30 Day Perf: -2.27 %
Volume (M): 412 52 Wk High: $ 20.69
Volume (M$): $ 6,736 52 Wk Avg: $9.85
Open: $16.30 52 Wk Low: $5.12



 Market Capitalization (Millions $) 1,044
 Shares Outstanding (Millions) 64
 Employees 14
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -100
 Cash Flow (TTM) (Millions $) 64
 Capital Exp. (TTM) (Millions $) 6

Edgewise Therapeutics Inc
Edgewise Therapeutics is a pharmaceutical company that is focused on the development of muscle-specific drugs. The company has a platform technology that allows it to create drugs that target specific muscles, which can help address debilitating diseases and conditions that affect the musculature system.

The companyes lead drug candidate is called EDG-5506, which is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is a genetic disorder that causes muscle degeneration and weakness, affecting around 1 in every 3,500 boys worldwide. There is currently no cure for the disease, and existing treatments only help manage the symptoms.

EDG-5506 works by inhibiting the activity of enzymes that are responsible for breaking down and degrading a protein called dystrophin, which is crucial for healthy muscle function. By blocking these enzymes, the drug can increase the production and availability of dystrophin, which can help improve muscle strength and function in patients with DMD.

In addition to its lead program in DMD, Edgewise Therapeutics is also working on developing drugs for other muscle-specific disorders, including facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy (LGMD), and Becker muscular dystrophy (BMD). The companyes platform technology allows it to target these specific muscles with precision, which can increase the efficacy and safety of its drugs.

Edgewise Therapeutics was founded in 2017 and is headquartered in Boulder, Colorado. The company has raised over $127 million in funding to date, including a $95 million Series B funding round in 2020 led by Sofinnova Investments and RA Capital Management. The companyes management team includes experienced industry veterans with backgrounds in drug development, clinical research, and business development.


   Company Address: 1715 38th St. Boulder 80301 CO
   Company Phone Number: 262-7002   Stock Exchange / Ticker: NASDAQ EWTX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Edgewise Therapeutics Inc

Edgewise Therapeutics Inc. Struggles to Meet Financial Expectations in Fourth Quarter Earnings Report



Edgewise Therapeutics Inc, a prominent muscle disease biopharmaceutical company, has recently faced significant challenges that have put its financial stability and future prospects into question. Despite high expectations from stockholders, the company has failed to generate any adjustments in its top-line revenue during the fiscal period of October to December 31, 2023. This article will delve into the company's operating loss, unsuccessful revenue generation attempts, and the implications of its underwritten offering of common stock.
Operating Loss and Declining Profits
One of the most significant concerns for Edgewise Therapeutics is its continuously widening operating loss. During the October to December 31, 2023 period, the company reported an operating loss of -$33.862 million, a significant decrease from the fourth quarter of 2022, where the loss was recorded at $17.317 million. This decline highlights the company's inability to effectively manage its operating expenses and control financial leakage.

Financing Agreement

Edgewise Therapeutics Raises $240 Million in Underwritten Offering to Bolster Muscle Disease Research

Published Fri, Jan 19 2024 1:37 PM UTC

Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
BOULDER, Colo. - Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, has revealed the pricing details for its underwritten offering of common stock. The company announced that it will be offering 21,818,182 shares at a price of $11.00 per share. Edgewise e...

Edgewise Therapeutics Inc

Edgewise Therapeutics Inc's First Quarter Report Reveals a Stunning Operating Deficit of $-25.704 Million in 2023

Edgewise Therapeutics Inc Returns Fall Below Industry Average
Edgewise Therapeutics Inc, a Major Pharmaceutical Preparations company, has reported its first-quarter 2023 earnings with a return on equity (ROE) of 0.39%, which is below its average return on equity of 2.99%. The decline is attributed to the fall in net income, which has led to a lower ranking compared to the previous quarter in the industry.
Moreover, within the Major Pharmaceutical Preparations industry, 43 other companies had a higher return on equity than Edgewise Therapeutics Inc. The company's total ranking has deteriorated, standing at 1613 compared to the previous quarter.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com